Healthpeak Q2 Preview: Revenue growth seen, but lab and rate headwinds dominate

What happened

Healthpeak Properties is set to report Q2 2026 results, with Zacks expecting higher revenues but cautioning that lab demand and senior care trends face pressure from rising interest expense. The DeepValue master report already flagged these headwinds, noting lab same-store occupancy slipped to 95% and recent impairments reflect oversupply. Despite a 7.3% dividend yield and low-single-digit FFO growth guidance, shares have remained below $17, largely pricing in the cyclical risks. Outpatient and CCRC segments continue to show steady performance, but lab softness and higher borrowing costs are capping upside. This earnings report will be a critical test of whether stable healthcare utilization can offset financing and supply pressures.

Implication

The Q2 report will likely show outpatient and CCRC resilience, but lab softness and higher interest costs will keep FFO growth in low-single digits. If lab metrics stabilize, the stock's ~7.3% yield and low multiple could attract value buyers, though a sustainable re-rating requires biopharma funding recovery. Conversely, further lab impairments or a drop in same-store NOI would validate the bear case and pressure the stock toward $16. The investment-grade balance sheet and safe dividend provide downside cushion, but risk-reward is balanced. For new positions, better entry points are near $16, while trimming makes sense above $21.

Thesis delta

The thesis remains unchanged: market pricing already discounts lab and rate headwinds, but upcoming earnings will either confirm the base case of contained risks or shift the balance toward the bear scenario. We maintain a cautious POTENTIAL BUY rating, with conviction dependent on actual Q2 numbers rather than pre-announcement speculation.